Epsilon M&A Deal Report - SBL Vaccin
Transaction Multiples for the Valuation of Private Companies
Crucell / SBL Vaccin
No EMAT :
17255
Announced Date :
21/11/2006
Type :
Exit ,Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Crucell
Target :
SBL Vaccin
Country :
Sweden
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
SBL develops, manufactures and markets vaccines and niche pharmaceuticals . Its primary research focus is the field of diarrhoeal diseases > Offers a broad range of travel vaccines, adult vaccines...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 131
| Date | Acquirer | Target | Country | Multiples | See details |
| 01/11/2006 | Allergan | Groupe Corneal Laboratoires | France | *** | 17254 |
| 21/10/2004 | Celgene | Penn T | Wales | *** | 17248 |
Source: Epsilon Research / EMAT
